Semaglutide Weight Management and Cardiovascular Risk Reduction
In the trial, insulin icodec appeared to have a safe profile and
showed superior HbA1c reduction vs daily basal insulin analogues
Superior reduction in HbA1c from baseline to 52 weeks
Overall hypoglycaemia in the trial
Change in HbA1c (%-points)
0.0
-0.4
-0.8
-1.2
-1.6
-2.0
0
13
Mean baseline HbA1c: 8.9%
26
39
On treatment
N
Once-weekly insulin
icodec
Once-daily basal insulin
analogues
(%) E RN (%) E R
Level 2: Clinically
significant Hypo*
64
(11.8) 104
0.19
42 (7.8) 76
0.13
-1.31
Level 3:
4
(0.7) 5
0.01
Severe Hypo*
-1.68
Level 3 or 2:
Severe or
64
(11.8)
104
0.19
45
45
(8.4)
81
0.14
clinically
significant Hypo*
52
52*
Time since randomisation (weeks)
Once-weekly insulin icodec
Once-daily basal insulin analogues
Note: Observed data are in-trial. Week 52* is estimated mean change in HbA1c based on ANCOVA with missing data derived
from multiple imputation. Insulin icodec was in combination with a dosing guide app. Once-daily basal insulin analogues
include insulin degludec and insulin glargine U100 and U300
Note: Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by blood
glycose meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external
assistance for recovery. Data is on-treatment.
N: Number of patients with one or more events; %: Percentage of patients with one or more events; E: Number of events;
R: Rate (number of events per patient year of exposure; Hypo: HypoglycaemiaView entire presentation